Trial Profile
Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2011
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 21 Jun 2011 New trial record